ATE494893T1 - Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer - Google Patents
Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmerInfo
- Publication number
- ATE494893T1 ATE494893T1 AT03809792T AT03809792T ATE494893T1 AT E494893 T1 ATE494893 T1 AT E494893T1 AT 03809792 T AT03809792 T AT 03809792T AT 03809792 T AT03809792 T AT 03809792T AT E494893 T1 ATE494893 T1 AT E494893T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfamates
- sulfamides
- sulfonamides
- gamma secretase
- secretase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0225474.6A GB0225474D0 (en) | 2002-11-01 | 2002-11-01 | Therapeutic agents |
| PCT/GB2003/004707 WO2004039370A1 (en) | 2002-11-01 | 2003-10-29 | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE494893T1 true ATE494893T1 (de) | 2011-01-15 |
Family
ID=9947009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03809792T ATE494893T1 (de) | 2002-11-01 | 2003-10-29 | Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7144910B2 (de) |
| EP (1) | EP1560580B1 (de) |
| JP (1) | JP4536517B2 (de) |
| AT (1) | ATE494893T1 (de) |
| AU (1) | AU2003276435B2 (de) |
| CA (1) | CA2503868C (de) |
| DE (1) | DE60335731D1 (de) |
| GB (1) | GB0225474D0 (de) |
| WO (1) | WO2004039370A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2404125C (en) * | 2000-03-20 | 2011-01-25 | Merck Sharp & Dohme Limited | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| US7399775B2 (en) | 2001-12-27 | 2008-07-15 | Daiichi Pharmaceutical Co., Ltd. | β-amyloid protein production/secretion inhibitor |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| RU2336270C2 (ru) | 2003-06-30 | 2008-10-20 | Дайити Фармасьютикал Ко., Лтд. | Гетероциклические метилсульфоновые производные |
| WO2005030731A1 (en) * | 2003-09-24 | 2005-04-07 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| US20080058316A1 (en) | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP2094836B1 (de) | 2006-11-15 | 2016-06-08 | Massachusetts Eye & Ear Infirmary | Erzeugung von innerohrzellen |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| EP2121633A2 (de) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden |
| EP2481408A3 (de) | 2007-03-01 | 2013-01-09 | Probiodrug AG | Neue Verwendung von Inhibitoren der Glutaminyl Cyclase |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US8377886B2 (en) * | 2007-09-14 | 2013-02-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| WO2010000372A2 (en) * | 2008-06-09 | 2010-01-07 | Ludwig-Maximilians-Universität München | New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| US10143711B2 (en) | 2008-11-24 | 2018-12-04 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| WO2011046774A1 (en) * | 2009-10-16 | 2011-04-21 | Merck Sharp & Dohme Corp. | Diaryl ether derivatives as notch sparing gamma secretase inhibitors |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (de) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina) |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3766975A1 (de) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3358013B1 (de) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| EP3970725B1 (de) | 2012-09-07 | 2025-08-20 | Massachusetts Eye & Ear Infirmary | Ein gamma-sekretase-inhibitor zur behandlung von gehörverlust |
| KR20150060724A (ko) | 2012-09-28 | 2015-06-03 | 머크 샤프 앤드 돔 코포레이션 | Erk 억제제인 신규 화합물 |
| DK2925888T3 (en) | 2012-11-28 | 2017-12-18 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS OF CANCER TREATMENT |
| EP2935263B1 (de) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituierte imidazopyridine als hdm2 inhibitoren |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| US20170314027A1 (en) | 2014-08-06 | 2017-11-02 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| EP3662909A1 (de) | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma-sekretase-modulatoren zur behandlung von immunsystemstörungen |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CA3013038A1 (en) | 2016-01-29 | 2017-08-03 | Massachusetts Eye And Ear Infirmary | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
| WO2017200762A2 (en) | 2016-05-16 | 2017-11-23 | The General Hospital Corporation | Human airway stem cells in lung epithelial engineering |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| CN110337291A (zh) | 2016-12-16 | 2019-10-15 | 帕珀莱恩医疗公司 | 治疗耳蜗突触病变的方法 |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833668B1 (de) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| BR112021002267A8 (pt) | 2018-08-07 | 2023-02-07 | Merck Sharp & Dohme | Inibidores de prmt5 |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CA3160153A1 (en) | 2019-12-17 | 2021-06-24 | Michelle Machacek | Prmt5 inhibitors |
| EP4076460B1 (de) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs |
| BR112022012015A2 (pt) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | Inibidores de prmt5 |
| EP4076459B1 (de) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| AU2021244215A1 (en) | 2020-03-26 | 2022-10-13 | Seagen Inc. | Methods of treating multiple myeloma |
| KR20250053961A (ko) | 2022-09-02 | 2025-04-22 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 토포이소머라제-1 억제제 제약 조성물 및 그의 용도 |
| TW202432099A (zh) | 2022-10-25 | 2024-08-16 | 美商默沙東有限責任公司 | 源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途 |
| IL321395A (en) | 2022-12-14 | 2025-08-01 | Merck Sharp & Dohme Llc | Auristatin cargo-linkers, pharmaceutical compounds, and their uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2404125C (en) * | 2000-03-20 | 2011-01-25 | Merck Sharp & Dohme Limited | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| ES2248397T3 (es) * | 2000-11-02 | 2006-03-16 | MERCK SHARP & DOHME LTD. | Sulfamidas como inhibidores de la gamma-secretasa. |
-
2002
- 2002-11-01 GB GBGB0225474.6A patent/GB0225474D0/en not_active Ceased
-
2003
- 2003-10-29 JP JP2004547808A patent/JP4536517B2/ja not_active Expired - Fee Related
- 2003-10-29 US US10/533,151 patent/US7144910B2/en not_active Expired - Fee Related
- 2003-10-29 AT AT03809792T patent/ATE494893T1/de not_active IP Right Cessation
- 2003-10-29 WO PCT/GB2003/004707 patent/WO2004039370A1/en not_active Ceased
- 2003-10-29 CA CA2503868A patent/CA2503868C/en not_active Expired - Fee Related
- 2003-10-29 DE DE60335731T patent/DE60335731D1/de not_active Expired - Lifetime
- 2003-10-29 EP EP03809792A patent/EP1560580B1/de not_active Expired - Lifetime
- 2003-10-29 AU AU2003276435A patent/AU2003276435B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB0225474D0 (en) | 2002-12-11 |
| CA2503868C (en) | 2011-09-20 |
| DE60335731D1 (de) | 2011-02-24 |
| EP1560580A1 (de) | 2005-08-10 |
| US20060069147A1 (en) | 2006-03-30 |
| JP2006506390A (ja) | 2006-02-23 |
| AU2003276435B2 (en) | 2008-10-16 |
| CA2503868A1 (en) | 2004-05-13 |
| AU2003276435A1 (en) | 2004-05-25 |
| JP4536517B2 (ja) | 2010-09-01 |
| EP1560580B1 (de) | 2011-01-12 |
| WO2004039370A1 (en) | 2004-05-13 |
| US7144910B2 (en) | 2006-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60335731D1 (de) | Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| ATE302753T1 (de) | Sulfamide als gamma-secretase-inhibitoren | |
| ATE444293T1 (de) | Cyclische sulfamide zur inhibierung von gamma- sekretase | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
| DE60328182D1 (de) | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase | |
| DE60144064D1 (de) | Sulfone, die die aktivität von gamma-secretase modulieren | |
| ATE354563T1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| NO20005237D0 (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
| TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
| DE60237725D1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| ATE348616T1 (de) | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer | |
| ATE353217T1 (de) | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren | |
| ATE524452T1 (de) | Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen. | |
| ES2282685T3 (es) | Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer. | |
| PE20071321A1 (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
| EA200700035A1 (ru) | Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders | |
| ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| BR0209149A (pt) | Ftalazinonas | |
| TW200736255A (en) | 5-(Substituted)-pyrazolopiperidines | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
| BR9813719A (pt) | Agentes terapêuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |